NEUROCRINE BIOSCIENCES INC Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value
NEUROCRINE BIOSCIENCES INC (NBIX) had Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value of $380.16 million as of 2018-09-30, per its 10-Q filed 2018-11-05.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue · last filed 2018-11-05
- 2018-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $380.16M.
- 2018-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $446.87M.
- 2018-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $534.74M.
- 2017-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $460.25M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value |
|---|---|
| 2018-09-30 | $380.16M 10-Q · filed 2018-11-05 |
| 2018-06-30 | $446.87M 10-Q · filed 2018-07-31 |
| 2018-03-31 | $534.74M 10-Q · filed 2018-04-30 |
| 2017-12-31 | $460.25M 10-Q · filed 2018-11-05 |
| 2017-09-30 | $407.95M 10-Q · filed 2017-11-01 |
| 2017-06-30 | $389.26M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $187.85M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $241.96M 10-K · filed 2018-02-13 |
| 2016-09-30 | $205.48M 10-Q · filed 2016-11-02 |
| 2016-06-30 | $157.43M 10-Q · filed 2016-08-03 |
| 2016-03-31 | $172.91M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $358.55M 10-K · filed 2017-02-14 |
| 2015-09-30 | $242.99M 10-Q · filed 2015-10-29 |
| 2015-06-30 | $299.64M 10-Q · filed 2015-07-29 |
| 2015-03-31 | $215.45M 10-Q · filed 2015-04-30 |
| 2014-12-31 | $167.46M 10-K · filed 2016-02-11 |
| 2014-09-30 | $164.37M 10-Q · filed 2014-11-04 |
| 2014-06-30 | $172.30M 10-Q · filed 2014-08-06 |
| 2014-03-31 | $109.04M 10-Q · filed 2014-05-01 |
| 2013-12-31 | $39.72M 10-K · filed 2015-02-09 |
| 2013-09-30 | $57.37M 10-Q · filed 2013-10-29 |
| 2013-06-30 | $68.23M 10-Q · filed 2013-07-26 |
| 2013-03-31 | $108.74M 10-Q · filed 2013-05-02 |
| 2012-12-31 | $67.49M 10-K · filed 2014-02-11 |
| 2012-09-30 | $89.58M 10-Q · filed 2012-10-31 |
| 2012-06-30 | $145.03M 10-Q · filed 2012-07-31 |
| 2011-12-31 | $65.27M 10-K · filed 2013-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |